Exosomes in Rheumatoid Arthritis: Unraveling Their Role as Biomarkers and Therapeutic Nanocarriers

Javeria[1], Aiman Irfan[1], Tasawar Iqbal[2*] and Sidra Altaf[3]

1. Department of Biochemistry, University of Agriculture, Faisalabad, Pakistan
2. Institute of Physiology and Pharmacology, University of Agriculture, Faisalabad, Pakistan
3. Department of Pharmacy, University of Agriculture Faisalabad, Pakistan

*Corresponding Author: **tasawariqbal177@gmail.com**

ABSTRACT

Undetermined etiology and unknown causes are both synonymous with the term autoimmune disease. It is the very reason behind the occurrence of synovial inflammation and subsequently joint erosion in cases of rheumatoid arthritis. Recent literature has provided plenty of evidence that places exosomes as key players in the pathogenesis of RA, and as such, they might be employed as biomarkers or therapeutic nanocarriers. Due to the fact that exosomal content includes miRNAs, cytokines, and proteins, this indicates that it contributes to the activation of synovial fibroblasts and immune regulation through inflammatory pathways. The presence of these exosomes in the blood and fluid of major joints makes them a good indicator of early diagnosis and monitoring advancement of diseases. Thereafter, newer methodologies have been developed over time, such as molecular docking and bioinformatics, to comprehend the interactions of exotics in coming years, opening new horizons for therapy.

Keywords: Exosomes, Rheumatoid Arthritis, Biomarkers, Therapeutic Nanocarriers, In Silico Analysis

To cite this article: Javeria, A Irfan, T Iqbal & S Altaf. Exosomes in Rheumatoid Arthritis: Unraveling Their Role as Biomarkers and Therapeutic Nanocarriers. Biological Times. 2025. March 4(3): 8-9.

Introduction

Arthritis is a systemic autoimmune disorder that is characterized by inflammation of synovial joints, results in chronic inflammation, destruction of cartilage, and sometimes the bone over time. This pathogenesis is critically dependent upon the immunological dysregulation of pro-inflammatory cytokines, TNF-alpha, IL-6, and IL-1 beta. The diagnosis of RA often gets delayed and is usually not pursued at an earlier opportunity because of improved methods of treatment, such as biologics and DMARDs. Defined by a specific size, between 30 and 150 nm in diameter, exosomes are a subtype of extracellular vesicle that has lately emerged as payloads for intercellular communication. A diverse panel of cells secretes extracellular vesicles that are of the diameter in nanometers; this means exosomes and includes immune cells, synovial fibroblasts, and mesenchymal stem cells. Mainly, bioactive molecules taken up inside control the immune response and signaling of inflammation in RA by proteins, lipids, microRNAs, messenger RNAs. Their capacity to carry molecular cargo positions them as strong prospects for biomarker identification and therapy. Exosome research in RA presents two significant opportunities. As biomarkers, the exosomes contained within synovial fluid and blood have potential as non-invasive diagnostic and predictive markers for disease severity and response to treatment. As therapeutic nanocarriers, exosomes may be designed to deliver drugs selectively with enhanced efficacy of biologics, siRNA drugs, and anti-inflammatory medicines and decreased systemic side effects. This review explores upon the burgeoning use of exosomes in RA pathology, their implications as biomarkers for diagnosis, and drug delivery. Also highlighted will be the computational and biochemical approaches used for studying exosomes, focusing on how in silico methodologies help us to deepen our knowledge in exosome-catalyzed mechanisms and also therapeutic applications [1].

Exosome Biology and Their Role in Rheumatoid Arthritis

Exosomes are small extracellular vesicles with diameters of 30 to 150 nm that are derived from the endosomal system of cells. They are secreted into the extracellular space upon fusion of multivesicular bodies with the plasma membrane. Virtually all cell types, including immune cells like T cells, B cells, and macrophages, synovial fibroblasts, and mesenchymal stem cells, secrete exosomes.These vesicles transport a wide range of bioactive molecules, ranging from lipids like phospholipids, sphingolipids, and cholesterol that play a role in membrane stability and cell signaling to proteins like enzymes, heat shock proteins, and tetraspanins like CD9, CD63, and CD81 that are vital for cellular interactions. Exosomes transport heterogeneous RNA molecules, including mRNAs, miRNAs, and long non-coding RNAs, involved in the regulation of genes and immunity. In RA, they transport specific miRNAs, cytokines, and proteins that take part in inflammation and joint degradation. miR-146a, miR-155, and miR-21 are involved in regulating immune processes, and miR-223 and miR-124 control the activity of synovial fibroblasts. Exosomal TNF-α, IL-6, and IL-1β cause chronic inflammation, whereas MMP-3 and MMP-9 are involved in cartilage degradation. Heat shock proteins are also DAMPs, which activate immune responses. Exosomes from RA patients increase the activity of fibroblast-like synoviocytes, which results in higher production of MMPs and pro-inflammatory cytokines, thus enhancing cartilage degradation, bone erosion, and chronic joint inflammation. These vesicles contribute to immune system dysregulation by allowing communication between different immune cells. In addition, exosomal miRNAs regulate T cell differentiation, specifically Th17 cells, which produce interleukin-17 (IL-17) and additionally exacerbate inflammatory responses. Exosomes enhance B cell activation, inducing autoantibody secretion and autoimmunity. Exosomes modulate dendritic cells, inducing antigen presentation and T cell activation, imposing RA formation. Exosomes transport inflammatory mediators, miRNAs, and proteins and modulate immune function and joint destruction. This data may provoke diagnostic and therapeutic innovations [2].

Exosomes as Biomarkers in Rheumatoid Arthritis

Exosomes are RA's non-invasive biomarkers that may impart disease status, severity, and therapeutic responsiveness information. Fluid containing exosomes, plasma, and serum enable early diagnosis. Exosomal molecular payload of proteins, miRNAs, and cytokines is variable in RA patients compared to healthy controls. miR-146a, miR-155, and miR-21 overexpressed in RA patients are pro-inflammatory, whereas low levels of miR-124 and miR-223 hamper control. Elevated TNF-α, IL-6, and metalloproteinases cause joint destruction. Disease status and treatment efficacy can also be quantified by markers found on the exosomes as well.By employing exosome-based monitoring, personalized treatment methods may be enabled, providing maximal therapy selection and reduced side effects. Their use notwithstanding, exosomes-based diagnosis will require tackling of some difficulties prior to use. The central problem is lack of standardization for the separation and characterization of exosomes. Processes like ultracentrifugation, size-exclusion chromatography, and immunoaffinity capture may have different grades of purity and concentration. Besides, lack of quantification and characterization protocols renders the reproducibility problem. Clinical validation and regulatory clearance are also major challenges, with most exosome-based research remaining in the preclinical phase and requiring large-scale validationRegulatory mechanisms for exosome-based diagnostics are being developed and must be further specified. Advanced bioinformatics and machine learning technologies are required to handle multi-omic data, e.g., exosomal miRNA, protein, and lipid biomarkers. Exosomes represent promising non-invasive RA diagnostic, prognostic, and therapeutic monitoring biomarkers. Their distinct molecular signature provides insight into disease mechanisms, allowing for personalized medicine. Standardization, clinical validation, and regulatory approvals must be achieved prior to their clinical use [3].

Exosomes as Therapeutic Nanocarriers in Rheumatoid Arthritis

Exosome-based therapy provides a targeted therapy for RA treatment with decreased systemic toxicity and increased efficacy. Exosomes as natural delivery vesicles are capable of delivering anti-inflammatory drugs, siRNAs, and miRNAs to the inflamed joints. Decorated exosomes carrying dexamethasone, methotrexate, or curcumin inhibit inflammation, while siRNAs against TNF-α and IL-6 are employed to modulate the immune response. Additionally, miRNAs such as miR-124 and miR-223 target synovial fibroblasts, indicating exosomes as promising nanocarriers for precision medicine in RA.The second approach is targeting surface modifications for enhanced delivery to inflamed joints. Exosomes with ligands or antibodies against synovial fibroblasts or inflamed endothelial cells are designed for targeted delivery, and hyaluronic acid-coated exosomes provide enhanced retention within arthritic joints, maintaining their therapeutic actions for longer. In RA treatments, such as biologic medications and disease-modifying anti-rheumatic drugs (DMARDs), exosome-based treatments have some advantages. Pathways of critical inflammation in RA are good therapeutic targets for exosome therapy. Anti-TNF siRNA or biologic-containing exosomes can neutralize TNF-α at inflamed joints and lower inflammation. Exosomal miRNAs, like miR-146a, can inhibit IL-6 signaling, reducing synovial inflammation. A novel strategy relies on exosome engineering coupled with Janus kinase inhibitors, such as tofacitinib, to inhibit cytokine signaling and alleviate RA symptoms. Exosome-based drug delivery is a new targeted therapeutic approach to treating RA, with highly effective and biocompatible treatment. They can be considered third-generation nanocarriers that hold great promise to transport anti-inflammatory drugs, siRNAs, and miRNAs selectively to synovial joints with substantially reduced systemic toxicity. The future research areas that hold the potential for realizing fully therapeutic gains in the treatment of RA comprise further perfecting exosome engineering for development, establishing methods for scaled production, and expanding clinical applications [4].

Table 1: Exosomes in Rheumatoid Arthritis: Unraveling Their Role as Biomarkers and Therapeutic Nanocarriers

Sr. No.	Aspect	Description	Role in RA	Potential Application
1	Source of Exosomes	Derived from various cells, including immune and synovial	Influence immune responses	Diagnostic and therapeutic potential
2	Exosomal Content	Proteins, lipids, RNA, and DNA	Reflect disease activity	Biomarker for RA diagnosis
3	Immune Modulation	Carry cytokines and miRNAs affecting immune cells	Regulate inflammation in RA	Targeting inflammatory pathways
4	Role in Synovial Inflammation	Influence fibroblast-like synoviocytes	Promote or inhibit synovial inflammation	Modulating synovial hyperplasia
5	Exosomes as Biomarkers	Contain disease-specific miRNAs and proteins	Distinguish RA from other diseases	Early and precise RA detection
6	Therapeutic Potential	Engineered exosomes deliver drugs/siRNA	Reduce inflammation and joint damage	Novel drug delivery approach
7	Exosomal miRNAs	Regulate gene expression in immune cells	Affect T-cell and B-cell responses	Modulating autoimmunity in RA
8	Cartilage Protection	Influence chondrocytes and osteoclasts	Prevent cartilage degradation	Potential in regenerative medicine
9	Drug Delivery via Exosomes	Encapsulate anti-inflammatory agents	Target inflamed tissues specifically	Precision medicine in RA treatment
10	Challenges and Future Directions	Stability, targeting, and large-scale production	Need for optimization in clinical applications	Translating exosome therapy into practice

Computational and Biochemical Approaches in Exosome Research

An investigation of exosomes in the treatment of rheumatoid arthritis is being pursued using a combination of computational and biochemical approaches to unravel its cargo contents, define biomarkers, and develop therapeutics. In silico methodologies, including molecular docking, network pharmacology, and bioinformatics, help in understanding the pathways mediated by exosomes. Meanwhile, the biochemically derived functional information about RA-derived exosomes is still under way. Major challenges include efficient data integration and standardization on one hand, emphasizing the urgent need for the AI-based computational frameworks. In this regard, computational approaches will play a significant role in demystifying the molecular structure and functional importance of exosomes in RA. For instance, molecular docking and dynamics simulations aid in reporting the binding affinity of drugs to Janus kinase inhibitors and anti-tumor necrosis factor drugs with exosomal receptors. Moreover, these techniques make predictions regarding exosomal microRNA (miRNA) interactions with target messenger RNAs (mRNAs), providing insights into gene regulation in RA. Network pharmacology combines disease pathways, miRNA-target networks, and protein-protein interactions to chart the role of exosomes in RA and discover novel exosome-secreted therapeutic targets for modulating inflammation. Moreover, bioinformatics software analyzes high-throughput sequence data to estimate disease-specific exosomal miRNA, mRNA, and protein signatures, and machine learning algorithms distinguish RA-derived from healthy individual exosomes, facilitating improved diagnostic specificity. Biochemical methods further shed light on the functional contribution of exosomes in RA pathogenesis. Proteomics methods, for example, mass spectrometry and liquid chromatography-mass spectrometry, determine proteins of exosomes involved in RA, such as TNF-α, IL-6, and matrix metalloproteinases. Lipidomics techniques, such as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and nuclear magnetic resonance spectroscopy, distinguish RA-exosomes from controls by determining lipid profiles related to membrane stability, signaling, and immune modulation. Transcriptomic methods, including RNA sequencing, can identify miRNAs, long non-coding RNAs, and mRNAs in exosomes, and differential expression analysis can be used to identify RA-specific miRNA signatures that can act as diagnostic and prognostic biomarkers. Notwithstanding remarkable advancements, a number of challenges prevent the complete potential of computational methods in exosome research. Computational and biochemical approach integration is revolutionizing RA exosome research with biomarker identification, disease modeling, and drug development. Computational methods like in silico molecular docking, network pharmacology, and AI-supported bioinformatics gain insights into the function of exosomes, and proteomics, lipidomics, and transcriptomics improve exosomal profiling. Resolving issues surrounding data standardization, AI-facilitated analysis, and computational complexity will be essential for the development of precision exosome-based therapeutics for RA therapy [5].

Future Perspectives and Challenges

The prospects for exosome-based diagnostics and therapeutics for rheumatoid arthritis (RA) are immense but also bring some challenges along. Clinical application of these methodologies can be made possible only if there is a standardization in exosome isolation, characterization, and validation methodologies. Regulatory and ethical issues should be addressed while using exosome-based nanomedicine to prove efficacy as well as safety. The use of artificial intelligence and machine learning could further improve biomarker discovery as well as therapy optimization. In addition, exosome-based treatments can potentially revolutionize RA therapy using personalized medicine, where the treatment can be tailored according to the patient's profile. Surmounting these challenges will be critical in moving exosome-based research into clinical applications [6].

Conclusion

Exosomes are a critical component in rheumatoid arthritis (RA) as they control immune response, are future biomarkers, and hold potential therapeutic strategies. Due to their potential to modify inflammation and facilitate the transfer of bioactive molecules, they find use in diagnosis as well as therapy for RA. Personalized medicine using exosomes has major promise for constructing patient-specific as well as target-oriented therapies. Nonetheless, factors such as standardization, scale-up production, and regulatory affairs have to be met. Additional studies are needed to break these obstacles and increase present knowledge. As continuous progress is made, exosome-based therapies may revolutionize RA treatment, providing more targeted, efficient, and personalized therapy in the future.

References

[1] K. Matsuda, N. Shiba, and K. Hiraoka, "New insights into the role of synovial fibroblasts leading to joint destruction in rheumatoid arthritis," Int. J. Mol. Sci., vol. 24, no. 6, p. 5173, 2023.
[2] Ahmad SR, Sarfaraz S, Shabbir ML, Moed HA, Husnain M, Najaf DE, Qureshi MA, Hammad M, Latif MF. Use of Nanoparticles in Modern Advancement of Medicines. 2024. 76-82.
[3] L. Duan et al., "Exosomes in Autoimmune Diseases: A Review of Mechanisms and Diagnostic Applications," Clin. Rev. Allergy Immunol., vol. 68, no. 1, p. 5, 2025.
[4] R. Heydari et al., "Exosomes as rheumatoid arthritis diagnostic biomarkers and therapeutic agents," Vaccines, vol. 11, no. 3, p. 687, 2023.
[5] M. J. Saadh et al., "Advancements in Exosome Proteins for Breast Cancer Diagnosis and Detection: With a Focus on Nanotechnology," AAPS PharmSciTech, vol. 25, no. 8, p. 276, 2024.
[6] Y. Ji et al., "Innovative diagnosis and therapeutic modalities: engineered exosomes in autoimmune disease," Int. J. Nanomedicine, pp. 3943–3956, 2024.